Business
Jupiter Endovascular Announces Completion of Enrollment in SPIRARE II Pivotal Trial
MENLO PARK, Calif., February 04, 2026--Jupiter Endovascular completes enrollment in a pivotal trial of its Vertex system with Transforming Fixation technology for pulmonary embolectomy.
About this update from Vertex Pharmaceuticals Incorporated
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":214,"url":"https://media.zenfs.com/en/business-wire.com/1f3c90ac01eb6bebe51f16a079673830"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7jeEzHpyHtZADPFKJJerGw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1f3c90ac01eb6bebe51f16a079673830","width":480,"height":214}},"lazy":false},{"type":"text","content":"Trial Evaluates Safety, Right Heart Functional Improvement, and Clinical Outcomes of Vertex Pulmonary Embolectomy System with Transforming Fixation (TFX)","length":153,"tagName":"p","attribs":{}},{"type":"text","content":"MENLO PARK, Calif., February 04, 2026--(BUSINESS WIRE)--Jupiter Endovascular, Inc., a medical technology company developing a new class of endovascular interventions using its proprietary Transforming Fixation (TFX) technology, today announced completion of patient enrollment in the SPIRARE II pivotal clinical trial evaluating the Vertex™ Pulmonary Embolectomy System in patients with acute, intermediate-risk pulmonary embolism (PE). The final subject was enrolled by Vikas Aggarwal, MD, Interventional Cardiologist at Henry Ford Hospital and the site’s Principal Investigator.","length":580,"tagName":"p"},{"type":"text","content":"SPIRARE II (NCT06576427) is a prospective, single-arm, multicenter pivotal study that enrolled 123 patients across 23 sites in Europe and the U.S. Trial endpoints characterize the procedural and clinical performance of PE treatment with the Vertex system across measures of safety, right heart function, and clinical improvement from the time of the procedure to 30 days post-procedure. The Vertex system incorporates Jupiter’s TFX technology to provide on-demand stability and control during transcatheter interventions in the pulmonary vasculature.","length":550,"tagName":"p"},{"type":"text","content":""Completion of enrollment in SPIRARE II represents a major milestone for both the SPIRARE clinical program and the broader PE field," said Catalin Toma, MD, Director of Interventional Cardiology at the UPMC Heart and Vascular Institute and the trial’s Global Co-Principal Investigator. "Pulmonary embolism is fundamentally a cardiac disease that places acute strain on the right heart....